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Abstract We examined whether extracellular signals regulate 
glycogen synthase kinase-3 (GSK-3) activity through tyrosine 
dephosphorylation of GSK-3. In resting Chinese hamster ovary 
cells overexpressing the human insulin receptor (CHO-IR cells), 
GSK-3 was tyrosine-phosphorylated and active. Insulin and 12- 
O-tetradecanoylphorbol 13-acetate (TPA) induced inactivation 
and tyrosine dephosphorylation of GSK-3. It is known that Ser-9 
of GSK-313 is phosphorylated in response to insulin and that the 
phosphorylation of this amino acid residue causes inactivation of 
GSK-313. However, the ectopically expressed GSK-3I] a9, in 
which the N-terminal nine amino acids of GSK-313 were deleted, 
was still inactivated and tyrosine-dephosphorylated in response to 
insulin. Protein phosphatase 2A treatment partially reversed 
insulin-induced GSK-31~ inactivation, but did not change GSK- 
3~ A9 inactivation. In CHO-IR cells where protein kinase C was 
down-regulated, TPA neither inactivated nor tyrosine-dephos- 
phorylated GSK-3. However, insulin inactivated and tyrosine- 
dephosphorylated GSK-3, although to a lesser degree than in the 
control cells. These results suggest that in addition to serine 
phosphorylation, tyrosine dephosphorylation of GSK-3 is also 
important for the regulation of GSK-3 activity in response to 
extracellular signals and that insulin regulates GSK-3 activity 
through both protein kinase C-dependent as well as protein 
kiuase C-independent pathways. 
l~ey words. GSK-3 ; Insulin; Tyrosine dephosphorylation; 
P~otein kinase C 
1. Introduction 
GSK-3 has originally been characterized as a serine/threo- 
rune kinase that phosphorylates and inactivates glycogen 
s) nthase [1,2] and subsequently demonstrated to be identical 
t~ protein kinase FA that activates ATP-Mg-dependent type-1 
p~otein phosphatase [24]. GSK-3 is now implicated in the 
regulation of several physiological responses in mammalian 
cells by phosphorylating many substrates including neuronal 
cell adhesion molecule [5], neurofilament [6], synapsin I [7], 
and tau [8], and transcription factors such as AP-1 [9,10] and 
c',clic AMP response element binding protein [11]. The 
cDNAs of GSK-3et and GSK-3[3 have been isolated and 
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rmtogen-activated protein kinase-activated protein; MAPK, mitogen- 
activated protein kinase; PKB, protein kinase B; PI, phosphatidyl- 
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phorbol 12,13-dibutyrate 
they encode protein kinases with molecular masses of 51 and 
47 kDa, respectively [12]. Mammalian GSK-31] is structurally 
and functionally homologous to the Drosophila zeste-white3/ 
shaggy gene product [13]. The shaggy gene product has been 
found to be required at several developmental stages during 
fruitfly embryogenesis for correct embryogenic segmentation 
[14,15]. In Saccharomyces cerevisiae, the MCK1 and MDS1 
encode serine/threonine kinases which are homologous to 
mammalian GSK-3 and Drosophila shaggy. The MCK1 and 
MDS1 gene products play a role in the chromosomal segrega- 
tion processes [16]. In Schizosaccharomyces pombe, the skpl+ 
gene product is a homolog of GSK-3 and regulates cytokinesis 
[17]. Xenopus GSK has been shown to regulate ventral differ- 
entiation during early Xenopus development [18]. Further- 
more, a Dictyostelium homolog (gskA) of GSK-3 has been 
found to be not essential for cell growth or the early stages 
of development but important for cellular differentiation [19]. 
Thus, GSK-3 is highly conserved through evolution. There- 
fore, it is possible that GSK-3 plays a fundamental role in 
cellular responses. 
Evidence has been accumulated on how GSK-3 activity is 
regulated in response to extracellular signals [20-26]. GSK-3 is 
directly phosphorylated and inactivated by 90 kDa ribosomal 
protein $6 kinase (p90 rSk, also known as MAPKAP kinase-1) 
which is activated by MAPK [27]. TPA enhances the phos- 
phorylation and inhibition of the ectopically expressed GSK- 
3~ when coexpressed with p90 rSk in HeLa $3 cells [28]. EGF- 
induced inhibition of GSK-3 is suppressed by expression of a 
dominant negative mutant of MAPK kinase in NIH3T3 cells 
[25]. These results indicate that p90 r~k mediates inactivation of 
GSK-3 by extracellular signals which activate the MAPK 
pathway [29]. The phosphorylation site of GSK-3 by p90 r~k 
has been identified as Ser-21 in GSK-3a and Ser-9 in GSK-313 
[27]. It has recently been found that protein kinase B (PKB, 
also known as Akt/RAC), which is activated by PI 3-kinase 
[30], phosphorylates the same serine residue of GSK-3 and 
inactivates GSK-3 [31]. It has also been reported that protein 
kinase C directly phosphorylates and inactivates GSK-3, 
although the phosphorylation site of GSK-3 by protein kinase 
C has not yet been identified [32]. These results clearly indi- 
cate that serine phosphorylation f GSK-3 induced by p90 rsk, 
PKB, or protein kinase C is important for the regulation of 
GSK-3 activity. 
It has been found that GSK-3 is highly phosphorylated on 
tyrosine in vivo and that tyrosine dephosphorylation f GSK- 
3 by tyrosine phosphatase r duces its kinase activity in vitro 
[33,34]. Furthermore, it has been reported that okadaic acid 
and TPA induce tyrosine dephosphorylation a d concurrent 
inactivation of GSK-3 in A431 cells [24,35]. Therefore, tyro- 
sine phosphorylation a d dephosphorylation f GSK-3 could 
be important for regulating its protein kinase activity. How- 
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ever, it is not clear whether extracellular signals regulate the 
phosphorylation state on tyrosine of GSK-3. In this paper we 
show that insulin and EGF  induce tyrosine dephosphoryla- 
tion and inactivation of GSK-3 in CHO- IR and COS cells 
and that GSK-3 activity is regulated by tyrosine dephosphor- 
ylation in addition to serine phosphorylation i  response to 
extracellular signals. 
2. Materials and methods 
2.1. Materials and chemicals 
CHO-IR cells were kindly provided by Dr. Y. Ebina (Tokushima 
University, Tokushima, Japan). PP2A was kindly supplied from Drs. 
M. Takeda and H. Usui (Hiroshima University School of Medicine, 
Hiroshima, Japan) [36]. Mammalian expression vector pCGN and the 
mouse anti-influenza virus HA1 monoclonal antibody 12CA5 [37] 
were provided by Dr. Q. Hu (University of California, San Francisco, 
CA, USA). pL1-3hyg was provided by Drs. A. Klippel (Chiron Corp., 
Emeryville, CA, USA). pBSSK/GSK-313 was kindly supplied by Dr. J. 
Woodgett (New Princess Margaret Hospital, Toronto, Canada). The 
GSK-3 peptide substrate (GSK peptide 1, YRRAAVPPSPSLSR- 
HSSPHQS(P)EDEEE) and the negative control peptide (GSK peptide 
2, YRRAAVPPSPSLSRHSSPHQSEDEEE) were synthesized by Dr. 
C.W. Turck (University of California, San Francisco, CA, USA). To 
make pCGN/GSK-313 and pGEX2T/GSK-313, pBSSK/GSK-313 was 
digested with BclI and EcoRI. The fragment was blunted with Klenow 
and inserted in the Sinai cut pCGN and Sinai cut pGEX2T to gen- 
erate pCGN/GSK-313 and pGEX2T/GSK-3[3, respectively. GSK-313 z~9, 
in which the N-terminal nine amino acids of GSK-313 were deleted, 
was synthesized by polymerase chain reaction. To prepare pCGN/ 
GSK-3[~ 9 and pGEX2T/GSK-313 z~9, the fragments encoding GSK- 
313 z~9 with Xbal and SmaI sites and with EcoRV and EcoRI sites 
were synthesized. The former fragment was digested with XbaI and 
Smal and inserted in the XbaI and SmaI cut pCGN to generate 
pCGN/GSK-313 Ag. The latter fragment was digested with EcoRV 
and EcoRl and inserted in the SmaI and EcoRI cut pGEX2T to 
generate pGEX2T/GSK-313 Ag. GST-fused to GSK-313 (GST-GSK- 
313) and GST-GSK-313 z~9 were purified from E. coli in accordance 
with the manufacturer's instructions (Pharmacia Biotech, Uppsala, 
Sweden). COS cells were obtained from the American Type Culture 
Collection. Other materials and chemicals were from commercial 
sources. 
2.2. Cell culture and fractionation of the cell extracts on Mono Q and 
Mono S column chromatography 
CHO-IR and COS cells were cultured at 37°C in F-12 containing 
10% fetal calf serum and Dulbecco's modified Eagle's medium con- 
taining 10% calf serum, respectively. After confluent cells (10-cm dia- 
meter dish) were deprived of serum for 24 h, CHO-IR and COS cells 
were washed with PBS and then stimulated for 5 min in serum-free 
medium with 500 nM TPA, 100 nM insulin, and 100 ng/ml EGF. The 
cells were then washed with PBS, suspended in 1 ml of buffer A (100 
mM Tris-HC1, pH 7.5; 2 mM EGTA, 100 mM KC1, 25 mM NaF, 
0.1% Triton X, 1 mM phenylmethylsulfonyl fluoride, 2/ag/ml aproti- 
nin, and 2 txg/ml leupeptin), and sonicated for 5 s ten times at 4°C. To 
this homogenate, 1 ml of buffer B (50 mM 13-glycerophosphate, pH 
7.5; 1 mM EGTA, 1 mM dithiothreitol, 0.5 mM sodium orthovana- 
date, 1 mM phenylmethylsulfonyl fluoride, 2 /ag/ml aprotinin, and 2 
/ag/ml leupeptin) was added. The mixture was centrifuged at 10 000 x g 
for 15 min at 4°C. The supernatant (3 mg of protein) was applied to 
Mono Q HR5/5 and Mono S HR5/5 columns connected in series, 
which were equilibrated with buffer B [26]. After the columns had 
been washed with 10 ml of buffer B and separated, the Mono S 
column was washed with 5 ml of buffer B containing 70 mM NaC1, 
and then the elution was performed with 3 ml of buffer B containing 
0.3 M NaC1 in a stepwise manner (3.5 /ag of protein). The GSK-3 
activity of an aliquot (10/.tl) of the eluates was assayed. To measure 
the protein level and phosphotyrosine content of GSK-3, aliquots of 
the eluates were probed with the anti-GSK-31~ and anti-phosphotyr- 
osine antibodies. 
2.3. GSK-3 assay 
The kinase activity of GSK-3 was assayed as described [20]. The 
samples were incubated with 50 laM GSK peptide 1 or GSK peptide 2
in 30/.tl of reaction mixture (20 mM Tris-HC1, pH 7.5; 5 mM MgC12, 
1 mM dithiothreitol, 50 txM [y-a2p]ATP (spec. act. 500-1000 cpm/ 
pmol)) for 20 min at 30°C. The reaction mixture was then spotted 
on phosphocellulose filters (Whatman P81). The filters were immersed 
in 150 mM phosphoric acid and then rinsed three times with fresh 
phosphoric acid. One unit of GSK-3 was defined as the amount which 
catalyzed the transfer of 1 pmol of phosphate into 1500 pmol of GSK 
peptide 1 for 20 min. For measuring HA-GSK-313 and HA-GSK-313 z~a 
activities, the extracts (0.5 mg of protein) of CHO-IR cells expressing 
HA-GSK-3[~ or HA-GSK-313 A~ were immunoprecipitated with the 
anti-HA antibody as described [38,39]. The GSK-3 activity of the 
precipitates was assayed as described above. All readings were within 
the linear ranges. 
2.4. Transfection 
Hygromycin-resistant celltransfectants were propagated in medium 
containing 200 /ag/ml hygromycin B. Transfection of CHO-IR cells 
with pCGN/GSK-313 or pCGN/GSK-31~ a9 and pL1-3hyg was carried 
out by using Lipofectamine in accordance with the manufacturer's 
instructions (Life Technologies, Inc., Gaithersburg, MD, USA). The 
cell lines expressing HA-GSK-313 or HA-GSK-3~ zx9 were established 
by selecting for resistance against hygromycin B. Colonies of the cells 
resistant to hygromycin B were selected at 14-20 days after transfec- 
tion. Subsequently, the cells expressing HA-GSK-313 or HA-GSK- 
313 z~9 among the hygromycin B-resistant cells were further selected 
by immunoblot analysis using the anti-HA antibody. 
2.5. PP2A treatment of HA-GSK-313 and HA-GSK-3~ 9 
The precipitated HA-GSK-313 and HA-GSK-313 ~9 were incubated 
with PP2A (50/aU) in the presence or absence of 2 ~tM okadaic acid 
in 50 /al of reaction mixture (50 mM Tris-HC1, pH 7.5; 0.5 mM 
dithiothreitol, 0.05% Triton X) for 30 min at 30°C. After incubation, 
okadaic acid was added and the precipitated enzymes were washed 
with 20 mM Tris-HC1 (pH 7.5) twice. The precipitates were used for 
GSK-3 assay. 
2.6. Other assays 
Prolonged treatment of CHO-IR cells with PDBu was performed as 
described [40]. The kinase activity of protein kinase C was assayed 
according to [40]. Protein concentrations were determined with bovine 
serum albumin as a standard [41]. The protein level and phosphotyr- 
osine content of GSK-3 were quantified using a CCD image sensor 
and ATTO Densitograph Ver 2.0 (ATTO Corp., Tokyo, Japan). 
3. Results and discussion 
3.1. Inactivation and tyrosine dephosphorylation f GSK-3 
induced by extracellular signals 
It has been reported that insulin inactivates GSK-3 in 
CHO- IR  cells and L6 myoblasts [20,22,23,26]. First we exam- 
ined whether insulin regulates tyrosine dephosphorylation of
GSK-3 as well as GSK-3 activity in CHO- IR cells. The kinase 
activity against GSK peptide 1 appeared in the eluates from 
the Mono S column by 0.3 M NaC1 (Fig. la). However, this 
kinase was not active against GSK peptide 2 (data not 
shown). These results indicated that this kinase activity was 
GSK-3. When CHO- IR cells were stimulated with TPA and 
insulin, GSK-3 activities were decreased (Fig. la). GSK-3 ac- 
tivities in control, TPA-stimulated, and insulin-stimulated 
CHO- IR cells were calculated to be 1490, 990, and 730 units, 
respectively. The decreases in GSK-3 activity upon stimula- 
tion with TPA and insulin were about 30 and 50%, respec- 
tively. When CHO- IR cells were stimulated with both TPA 
and insulin, GSK-3 activity was decreased to a level which 
was inhibited by insulin alone (Fig. la). These results were 
consistent with previous observations [20,22,23,26]. Immuno- 
blot analyses of the eluates with the anti-GSK-3[5 and anti- 
phosphotyrosine antibodies were performed and then the pro- 
tein level and phosphotyrosine content of GSK-3 were quan- 
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tiffed using the CCD image sensor. When the protein level and 
phosphotyrosine content of known amounts of GST-GSK-3[3 
purified from E. coli were determined by this method, the 
densities of the bands on the nitrocellulose sheets were pro- 
portional to the amounts (2.5-50 ng) of GST-GSK-3~ (data 
not shown). The protein levels of GSK-3]3 in control, TPA- 
stimulated, and insulin-stimulated CHO-IR cells were similar 
(Fig. lb,c), while the stimulation of CHO-IR cells with TPA 
and insulin resulted in 40 and 70% reduction of the phospho- 
tyrosine content of GSK-3 (Fig. lb,c). The stimulation of 
CHO-IR cells with both TPA and insulin resulted in the 
same reduction of phosphotyrosine content as that caused 
by insulin alone (data not shown). When COS cells were stim- 
ulated with TPA and EGF, GSK-3 activities were decreased 
by about 25 and 50%, respectively (Fig. 2a). Approx. 35 and 
65% of the phosphotyrosine content of GSK-3 were reduced 
in TPA- and EGF-stimulated COS cells compared to control 
cells under the conditions that the protein levels of GSK-3~ in 
control, EGF-stimulated, and TPA-stimulated COS cells were 
similar (Fig. 2b,c). Taken together, these results indicate that 
extracellular signals such as insulin an~l EGF induce tyrosine 
dephosphorylation a d inactivation of GSK-3. 
GSK-3 is phosphorylated on a unique tyrosine residue and 
active in resting cells [33]. The conservation of the region of 
protein encompassing this residue implies a critical role for 
this covalent modification [33]. GSK-3 produced in E. coli is 
also tyrosine-phosphorylated an  a kinase-negative mutant of 
GSK-3 is not tyrosine-phosphorylated [34]. Therefore, tyro- 
sine phosphorylation of GSK-3 should be due to autophos- 
phorylation and not to a tyrosine kinase which phosphory- 
lates GSK-3. Tyr-216 is a phosphorylation site of GSK-3~ 
and the substitution of Phe for Tyr-216 impairs its kinase 
activity [33]. These observations suggest that tyrosine dephos- 
phorylation regulates GSK-3 activity in intact cells. It has 
been shown that TPA and okadaic acid induce tyrosine de- 
phosphorylation of GSK-3 and concurrently inactivate it in 
A431 cells [24,35]. However, neither TPA nor okadaic acid is 
a physiological agonist. We have for the first time demon- 
strated that extracellular signals such as insulin and EGF 
tyrosine-dephosphorylate and inactivate GSK-3 in CHO-IR 
and COS cells. The degree of tyrosine dephosphorylation f 
GSK-3 was more than that of its inactivation when the cells 
were treated with insulin, EGF, and TPA. Although we do 
not know the exact reasons for these observations, one pos- 
sibility is that when GSK-3 is inactivated, an unknown mech- 
Fig. 1. Inactivation and tyrosine dephosphorylation f GSK-3 in- 
duced by TPA and insulin in CHO-IR cells. (a) GSK-3 activity. 
After CHO-IR cells were left untreated (control) or stimulated with 
TPA, insulin, or both TPA and insulin, the cell extracts were sub- 
jected to Mono Q and Mono S column chromatography. GSK-3 ac- 
tivities of the eluates were assayed against GSK peptide 1. The re- 
sults shown are expressed as means+S.E.M, of three independent 
experiments. (b) Immunoblot analysis of phosphotyrosine of GSK- 
3. Aliquots of the eluates prepared in (a) were probed with the anti- 
GSK-3I~ and anti-phosphotyrosine a tibodies, pY, phosphotyrosine; 
Ab, antibody. The results shown are representative of three inde- 
pendent experiments. (c) Densitometric quantification of the protein 
level and phosphotyrosine content of GSK-3. The protein level 
(hatched bars) and phosphotyrosine content (stippled bars) of GSK- 
3 in (b) were quantified using the CCD image sensor (ATTO Densi- 
tograph). The results shown are representative of three independent 
experiments. 
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Fig. 2. Inactivation and tyrosine dephosphorylation f GSK-3 induced by TPA and EGF in COS cells. (a) GSK-3 activity. GSK-3 activities of 
the eluates from Mono S column chromatography of COS cells left untreated (control) or stimulated with TPA or EGF were assayed against 
GSK peptide 1. The results shown are expressed as means + S.E.M. of three independent experiments. (b) Densitometric quantification of the 
protein level and phosphotyrosine content of GSK-3. Aliquots of the eluates prepared in (a) were probed with the anti-GSK-3[3 and anti-phos- 
photyrosine antibodies, and then the protein level (hatched bars) and phosphotyrosine content (stippled bars) of GSK-3 were quantified using 
the CCD image sensor. The results shown are representative of three independent experiments. (c) Immunoblot analysis of phosphotyrosine of 
GSK-3. Aliquots of the eluates prepared in (a) were probed with the anti-phosphotyrosine antibody, pY, phosphotyrosine; Ab, antibody. The 
results shown are representative of three independent experiments. 
Fig. 3. Inactivation and tyrosine dephosphorylation f GSK-313 z~° induced by insulin. (a) Protein levels of HA-GSK-3~I and HA-GSK-313 z~9. 
After CHO-IR cells expressing HA-GSK-313 (lanes 1,2) or HA-GSK-3[V x9 (lanes 3,4) were left untreated (lanes 1,3) or stimulated with insulin 
(lanes 2,4), the cell extracts were immunoprecipitated with the anti-HA antibody. The precipitates were probed with the anti-GSK-313 antibody. 
The arrow and arrowhead indicate the positions of HA-GSK-313 and HA-GSK-31V xg, respectively. Ig, immunoglobulin. The results shown are 
representative of three independent experiments. (b) Inactivation of HA-GSK-313 and HA-GSK-313 zx9 by insulin and TPA. After CHO-IR cells 
expressing HA-GSK-313 or HA-GSK-313 z~9 were left untreated (control) or stimulated with TPA or insulin, the cell extracts were immunopreci- 
pitated with the anti-HA antibody. The precipitates were assayed for GSK-3 activity. The results shown are expressed as means + S.E.M. of 
eight independent experiments. *Differences ignificant at least P< 0.05. (c) PP2A treatment. The precipitated HA-GSK-31$ and HA-GSK-313a9 
prepared in (a) were treated with PP2A in the presence (hatched bars) or absence (stippled bars) of okadaic acid. After this treatment, GSK-3 
activities were measured. (d) Tyrosine dephosphorylation f GSK-313 z~9 in response to insulin. The precipitated HA-GSK-313 zx9 prepared in (a) 
were probed with the anti-GSK-3~ and anti-phosphotyrosine antibodies. The protein level (hatched bars) and phosphotyrosine content (stippled 
bars) of HA-GSK-3~ z~9 were quantified using CCD image sensor. The results shown are representative of three independent experiments. 
H. Murai et al./FEBS Letters 392 (1996) 153-160 
(a) 
exDressed prbteln HA-GSK-3B.  HA-GSK.3 f l  A9  
insulin '- + 





~o++-~ . " ~+' 
. #. .~ ~,\o,,t 
I I I I 
HA-GSK-3[~ HA-GSK-3P A9 
(c) 







PP2A+ + + + + + + + 
Okada icac id+ - + - + - + - 
I I I I 
HA-GSK-3p HA.GSK-3~ A9 
0 
Cont ro l  Insu l in  ~., 
157 
158 H. Murai et al./FEBS Letters 392 (1996) 153-160 
• 
!, 
I I I I I I 1 I 
No  t reatment  PDBu t reatment  No  t reatment  PDBu t reatment  
Fig. 4. Involvement of protein kinase C in insulin-dependent i activation and tyrosine dephosphorylation of GSK-3. (a) Effect of down-regula- 
tion of protein kinase C on insulin-dependent i activation of GSK-3. After CHO-IR cells were treated with or without PDBu for 24 h, GSK-3 
activities of the eluates from Mono S column chromatography of the cells left untreated (control) or stimulated with TPA or insulin were as- 
sayed. The results hown are expressed as means _+ S.E.M. of three independent experiments. (b) Effect of down-regulation of protein kinase C 
on insulin-dependent tyrosine dephosphorylation of GSK-3. Aliquots of the eluates prepared in (a) were probed with the anti-GSK-313 and 
anti-phosphotyrosine a tibodies, and then the protein level (hatched bars) and phosphotyrosine content (stippled bars) of GSK-3 of the cells 
left untreated (control) or stimulated with TPA or insulin were quantified using the CCD image sensor. The results hown are representative of 
three independent experiments. 
anism might work to prevent he inhibition of GSK-3 activity 
without affecting tyrosine dephosphorylation. 
3.2. Inactivation and tyrosine dephosphorylation f GSK-3~ A9 
induced by insulin 
It is known that insulin and EGF activate p90 rsk and PKB 
and that these kinases phosphorylate Ser-21 and Ser-9 of 
GSK-3c~ and GSK-313, respectively, and inactivate GSK-3 
[20,21,23,25,27,31]. Our results hown in Figs. 1 and 2 suggest 
that tyrosine dephosphorylation f GSK-3 may be involved in 
extracellular signal-dependent i activation of GSK-3. How- 
ever, we cannot exclude the possibility that extracellular sig- 
nals activate p90 rSk and PKB and induce the phosphorylation 
of GSK-3 thereby inactivating and tyrosine-dephosphorylat- 
ing GSK-3. Therefore, we synthesized GSK-31] Ag, in which 
the N-terminal nine amino acids were deleted. When GST- 
GSK-313 and GST-GSK-3~ A9 purified from E. coli were as- 
sayed against GSK peptide 1, both proteins had the same 
activity (data not shown). CHO-IR cells expressing wild- 
type GSK-313 and GSK-3I~ A9 were made. These GSK-313s 
were tagged with the HA epitope at the N-terminus. After 
these cells were stimulated with insulin, HA-GSK-313 and 
HA-GSK-3~ A9 were immunoprecipitated with the anti-HA 
antibody. Almost equal amounts of HA-GSK-313 and HA- 
GSK-313 A9 were precipitated as assessed by immunoblot anal- 
ysis using the anti-GSK-31] antibody (Fig. 3a). The basal 
activities of HA-GSK-31~ and HA-GSK-313 a° were almost 
the same. Insulin decreased the activities of HA-GSK-3~ 
and HA-GSK-31~ Ao by 40 and 20%, respectively (Fig. 3b). 
TPA also decreased the activities of HA-GSK-313 and HA- 
GSK-31] A9 by 20 and 10%, respectively (Fig. 3b). Although 
the decrease in HA-GSK-31~ a° activity by insulin and TPA 
appeared to be small, these results were reproducible and 
statistically significant. The decrease in GSK-3[3 activity in- 
duced by insulin was partially restored by PP2A treatment, 
while that of GSK-313A9 activity induced by insulin was not 
changed (Fig. 3c). Furthermore, insulin decreased the phos- 
photyrosine content of HA-GSK-3[3 A9 by 40% (Fig. 3d). 
These results clearly demonstrate hat inactivation and tyro- 
sine dephosphorylation f GSK-3 induced by insulin occurs 
without phosphorylation of Ser°9. Therefore, it is possible 
that not only serine phosphorylation but also tyrosine dephos- 
phorylation of GSK-3 is important for the extracellular sig- 
nal-dependent regulation of GSK-3 activity. 
3.3. Involvement of protein kinase C in insulin-induced inactiva- 
tion and tyrosine dephosphorylation f GSK-3 
The activation of protein kinase C by insulin has been im- 
plicated in various cell functions such as the stimulation of 
glucose transport in BC3H1 myocytes and rat soleus muscle 
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[42], c-fos expression in neurons [43], and the activation of 
amino acid transport in hepatocytes [44]. However, it has 
been reported that protein kinase C is not required in several 
insulin-dependent actions [44,45]. We examined whether pro- 
tein kinase C is involved in insulin-induced inactivation and 
tyTosine dephosphorylation f GSK-3. For this experiment, 
C}/O-IR cells were treated with 800 nM PDBu for 24 h. After 
this treatment, he protein kinase C activity activated by phos- 
p! atidylserine, TPA, and Ca 2+ was reduced to less than 5% of 
that of the control cells (data not shown). These results clearly 
indicated that protein kinase C was markedly down-regulated 
ard reduced by prolonged treatment with PDBu. The basal 
ac:ivity of GSK-3 and the protein level of GSK-313 of CHO- 
IR cells treated with PDBu were almost similar with those of 
th: control cells (Fig. 4a,b). In CHO-IR cells where protein 
kiaase C activity was markedly decreased, TPA-dependent 
G';K-3 inactivation was completely abolished (Fig. 4a) and 
T!'A did not induce tyrosine dephosphorylation f GSK-3 
(I-ig. 4b). However, insulin still inactivated and tyrosine-de- 
pl~osphorylated GSK-3 in CHO-IR cells where protein kinase 
C was down-regulated, although the degree was attenuated 
ccmpared to control cells (Fig. 4a,b). These results suggest 
that insulin regulates GSK-3 activity and its tyrosine dephos- 
pl'.orylation through both protein kinase C-dependent as well 
as protein kinase C-independent pathways. 
Although we do not know how protein kinase C induces 
t2~ "osine dephosphorylation f GSK-3, it is intriguing to spec- 
ulate that protein kinase C activates a tyrosine phosphatase 
re- GSK-3. Two mechanisms of the inhibitory action of pro- 
ten  kinase C for GSK-3 have been reported. The first is that 
p~ 3tein kinase C directly phosphorylates and inactivates 
GgK-3 [32], the second being that protein kinase C regulates 
GgK-3 through MAPKAP kinase-1 by activating the MAPK 
p;~thway [28]. It is possible that several pathways through 
pl 3tein kinase C activated by extracellular signals regulate 
G ~K-3. Our results also suggest hat there is a protein kinase 
C independent pathway which is involved in the regulatory 
m~'chanism of GSK-3 by insulin. These results are consistent 
w th the observations that inactivation and tyrosine dephos- 
pl orylation of GSK-3 induced by insulin is more significant 
tb ~n those induced by TPA. Recently, it has been shown that 
in ;ulin and platelet-derived growth factor activate PI 3-kinase, 
t~ ~t PI-3-phosphate, a product of PI 3-kinase, activates PKB, 
aJd that PKB phosphorylates and inactivates GSK-3 [30,31]. 
Tt is  pathway could be one of the protein kinase C-indepen- 
dent pathways in insulin-induced inactivation of GSK-3. The 
m,~chanisms that induce tyrosine dephosphorylation f GSK-3 
in tependently of protein kinase C in response to insulin re- 
in tin to be clarified. 
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